New Developments in Follicular Lymphoma: Treatment Guidance and Clinical Resources

Gain insights for the multidisciplinary team on leveraging current and emerging therapies for optimal care of patients with follicular lymphoma across multiple settings with expert-authored commentaries a text module and downloadable PowerPoint slides and clinical resource PDF. Then learn how the experts would treat your patients in the frontline and relapsed/refractory settings with an updated decision support tool.

Share

Program Content

Activities

Tazemetostat for R/R FL
My Take on the Recent Approval of Tazemetostat for Relapsed/Refractory Follicular Lymphoma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 04, 2020

Expires: August 03, 2021

Updated FL Tool
An Updated Interactive Treatment Decision Support Tool for Follicular Lymphoma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 18, 2021

Expires: March 17, 2022

Activities

FL Clinical Resource
Follicular Lymphoma Clinical Resource: Current Treatment Landscape and Treatment-Related Toxicity Management Guide
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: September 30, 2020

Expires: September 29, 2021

Activities

EP: FL Management Advances
ExpressPoints: Critical Advances in the Management of Follicular Lymphoma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 14, 2020

Expires: October 13, 2021

Optimizing FL Management
Practical Guidance on Optimizing Management of Follicular Lymphoma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 14, 2020

Expires: October 13, 2021

Activities

Follicular Lymphoma Treatment Tool
Interactive Decision Support Tool: Expert Treatment Recommendations for Patients With Newly Diagnosed or Relapsed/Refractory Follicular Lymphoma
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: March 01, 2021

Expires: February 28, 2022

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Celgene

Epizyme, Inc.